Summit Therapeutics (SMMT) Common Equity (2018 - 2026)
Summit Therapeutics' (SMMT) quarterly Common Equity came in at $630.0 million in Q2 2026, up 142.83% YoY from $259.4 million in Q2 2025, and up 15.4% on a QoQ basis from $545.9 million in Q1 2026.
Summit Therapeutics (SMMT) Common Equity (2018 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 9 years of Common Equity data on file, last reported at $630.0 million in Q2 2026.
- Quarterly Common Equity rose 142.83% year-over-year to $630.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $630.0 million (up 142.83% YoY) and the FY2025 annual result came in at $658.9 million, up 69.48% from the prior year.
- Common Equity climbed to $630.0 million in Q2 2026, from $545.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $658.9 million in Q4 2025 to a low of $44.2 million in Q1 2024.
- A 5-year average of $250.1 million and a median of $162.9 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity slumped 66.88% — and 2025, when it jumped 678.85%.
- Tracing SMMT's Common Equity over 5 years: stood at $126.7 million in 2022, then tumbled by 38.66% to $77.7 million in 2023, then jumped by 400.37% to $388.7 million in 2024, then soared by 69.48% to $658.9 million in 2025, then declined by 4.38% to $630.0 million in 2026.
- The last three Common Equity figures came in at $630.0 million (Q2 2026), $545.9 million (Q1 2026), and $658.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 629.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 629.98 Mn |
| Mar 31, 2026 | 545.93 Mn |
| Dec 31, 2025 | 658.86 Mn |
| Sep 30, 2025 | 192.26 Mn |
| Jun 30, 2025 | 259.44 Mn |
| Mar 31, 2025 | 344.33 Mn |
| Dec 31, 2024 | 388.75 Mn |
| Sep 30, 2024 | 437.92 Mn |
| Jun 30, 2024 | 195.08 Mn |
| Mar 31, 2024 | 44.21 Mn |
| Dec 31, 2023 | 77.69 Mn |
| Sep 30, 2023 | 99.38 Mn |
| Jun 30, 2023 | 119.60 Mn |
| Mar 31, 2023 | 133.48 Mn |
| Dec 31, 2022 | 126.65 Mn |
| Sep 30, 2022 | 133.25 Mn |
| Jun 30, 2022 | 51.32 Mn |
| Mar 31, 2022 | 64.41 Mn |
| Dec 31, 2021 | 83.28 Mn |
| Sep 30, 2021 | 102.30 Mn |